Suttichaimongkol Tanita, Hwang Sung Wook, Coelho-Prabhu Nayantara, Kisiel John B, Ye Byong Duk, Yang Suk-Kyun, Loftus Edward V, Park Sang Hyoung
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Therap Adv Gastroenterol. 2024 Sep 18;17:17562848241275342. doi: 10.1177/17562848241275342. eCollection 2024.
Crohn's disease (CD) exhibits variability in colorectal cancer (CRC) incidence and prognostic factors due to diverse clinical and behavioral characteristics, presenting inconsistencies between Western and Eastern patients.
This study compared clinical characteristics between CD patients with CRC from the US and Korean tertiary referral centers and defined the prognostic factors related to mortality.
Retrospective study.
We reviewed the electronic medical records of 236 adult CD patients with colorectal adenocarcinoma evaluated at Mayo Clinic Rochester, Florida, or Arizona ( = 200) and Asan Medical Center in Korea ( = 36) between January 1989 and August 2022.
Asan patients had a younger age, shorter CD duration, more colonic involvement (L2 plus L3), penetrating behavior, perianal fistula, and shorter biological treatment duration before CRC diagnosis than Mayo patients. Furthermore, despite significant differences in body mass index, smoking status, primary sclerosing cholangitis, immunomodulators, CRC diagnosis period, clinical presentation, CRC location, surgery, and some histopathological details between the two groups, overall survival was not statistically different ( value, 0.29, log-rank test). Advanced age (adjusted hazard ratio (aHR), 1.03 per year; 95% confidence interval (CI), 1.01-1.04; value, <0.01), unresectable CRC (aHR, 5.02; 95% CI, 2.49-10.12; value, <0.01), and advanced CRC stage (aHR, 1.45 per stage; 95% CI, 1.07-1.97; value, 0.02) were significantly associated with increased risk of death. CD remission at CRC diagnosis (aHR, 0.26; 95% CI, 0.08-0.91; value, 0.04), CRC diagnosis period of 2011-2022 (aHR relative to 1989-2000, 0.46; 95% CI, 0.25-0.87; value, 0.02), and CRC diagnosis by surveillance (aHR, 0.56; 95% CI, 0.32-0.98; value, 0.04) were significantly associated with decreased risk of death.
Notably, some clinical features of CD with CRC differed between Asan and Mayo patients; however, overall survival was not different. CD remission, CRC surveillance, and more recent diagnosis of CRC were associated with a reduced risk of death.
克罗恩病(CD)由于临床和行为特征多样,在结直肠癌(CRC)发病率和预后因素方面存在差异,导致东西方患者之间存在不一致性。
本研究比较了来自美国和韩国三级转诊中心的CD合并CRC患者的临床特征,并确定了与死亡率相关的预后因素。
回顾性研究。
我们回顾了1989年1月至2022年8月期间在梅奥诊所罗切斯特、佛罗里达州或亚利桑那州(n = 200)以及韩国峨山医学中心(n = 36)评估的236例成年CD合并大肠腺癌患者的电子病历。
峨山患者在CRC诊断前年龄更小、CD病程更短、结肠受累更多(L2加L3)、穿透性病变行为、肛周瘘管以及生物治疗持续时间更短。此外,尽管两组在体重指数、吸烟状况、原发性硬化性胆管炎、免疫调节剂、CRC诊断时期、临床表现、CRC位置、手术以及一些组织病理学细节方面存在显著差异,但总生存率无统计学差异(P值,0.29,对数秩检验)。高龄(调整后风险比(aHR),每年1.03;95%置信区间(CI),1.01 - 1.04;P值,<0.01)、不可切除的CRC(aHR,5.02;95% CI,2.49 - 10.12;P值,<0.01)以及晚期CRC分期(aHR,每增加一期1.45;95% CI,1.07 - 1.97;P值,0.02)与死亡风险增加显著相关。CRC诊断时CD缓解(aHR,0.26;95% CI,0.08 - 0.91;P值,0.04)、2011 - 2022年的CRC诊断时期(相对于1989 - 2000年的aHR,0.46;95% CI,0.25 - 0.87;P值,0.02)以及通过监测进行CRC诊断(aHR,0.56;95% CI,0.32 - 0.98;P值,0.04)与死亡风险降低显著相关。
值得注意的是,峨山和梅奥患者中CD合并CRC的一些临床特征有所不同;然而,总生存率并无差异。CD缓解、CRC监测以及更近期的CRC诊断与死亡风险降低相关。